Williams R Sanders
Known title: DirectorCIK: 0001375347
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Amgen Outperforms Market Amid Dow Jones Rotation. Amgen has recently exceeded broader market returns, a trend highlighted in recent analyses of Dow Jones stocks making bullish moves during defensive market rotations. This performance contrasts with peers like Merck, where analysts are comparing dividend growth potential. While the stock shows relative strength, it remains within its 52-week range, with the average analyst target price set significantly above current levels.
Transaction History
| LH | ▲ Buy | Option Exercise | 947 | — | 2/7/2024 | View on chart |
| AMGN | ▲ Buy | Grant | 939 | $0 | 5/19/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 742 | — | 2/11/2023 | View on chart |
| AMGN | ▼ Sell | Open Market | 200 | $50K | 8/22/2022 | View on chart |
| AMGN | ▼ Sell | Open Market | 600 | $150K | 5/23/2022 | View on chart |
| AMGN | ▲ Buy | Grant | 855 | $0 | 5/17/2022 | View on chart |
| LH | ▼ Sell | Open Market | 572 | $156K | 3/25/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 771 | — | 2/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M
Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.